ID: ALA2435401

Max Phase: Preclinical

Molecular Formula: C25H31N5O

Molecular Weight: 417.56

Molecule Type: Small molecule

Representations

Canonical SMILES:  Cc1cc(C)nc(N2CCC3(CCCN(Cc4cn(C)c5ccccc45)C3=O)CC2)n1

Standard InChI:  InChI=1S/C25H31N5O/c1-18-15-19(2)27-24(26-18)29-13-10-25(11-14-29)9-6-12-30(23(25)31)17-20-16-28(3)22-8-5-4-7-21(20)22/h4-5,7-8,15-16H,6,9-14,17H2,1-3H3

Standard InChI Key:  PVPZCYTVIMWDJE-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 417.56

Molecular Weight (Monoisotopic): 417.2529

AlogP: 3.99

#Rotatable Bonds: 3

Polar Surface Area: 54.26

Molecular Species: NEUTRAL

HBA: 5

HBD: 0

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 5.00

CX LogP: 3.39

CX LogD: 3.39

Aromatic Rings: 3

Heavy Atoms: 31

QED Weighted: 0.65

Np Likeness Score: -1.01

References

1. Betschart C, Hintermann S, Behnke D, Cotesta S, Fendt M, Gee CE, Jacobson LH, Laue G, Ofner S, Chaudhari V, Badiger S, Pandit C, Wagner J, Hoyer D..  (2013)  Identification of a novel series of orexin receptor antagonists with a distinct effect on sleep architecture for the treatment of insomnia.,  56  (19): [PMID:23964859] [10.1021/jm4007627]

Source

Source(1):

• Scientific Literature